Coronavirus Infection - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Coronavirus Infection - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Coronavirus Infection - Pipeline Review, H1 2015', provides an overview of the Coronavirus Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Coronavirus Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Coronavirus Infection Overview 7
Therapeutics Development 8
Pipeline Products for Coronavirus Infection - Overview 8
Pipeline Products for Coronavirus Infection - Comparative Analysis 9
Coronavirus Infection - Therapeutics under Development by Companies 10
Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 11
Coronavirus Infection - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Coronavirus Infection - Products under Development by Companies 15
Coronavirus Infection - Products under Investigation by Universities/Institutes 16
Coronavirus Infection - Companies Involved in Therapeutics Development 17
AstraZeneca PLC 17
Hemispherx Biopharma, Inc. 18
Humabs BioMed SA 19
Inovio Pharmaceuticals, Inc. 20
NanoViricides, Inc. 21
Novavax, Inc. 22
Coronavirus Infection - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Cell Therapy for Coronavirus Infection - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
coronavirus vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
EMER-IT - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
interferon alfa-n3 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
interferon beta-1a - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MERS-COV - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MERS-CoV Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
middle east respiratory syndrome coronavirus vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Monoclonal Antibody for Coronavirus Infection - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Monoclonal Antibody for MERS and SARS - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Inhibit Viral Protease for Viral Infections - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Vaccine for Respiratory and Infectious Diseases - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Coronavirus Infection - Recent Pipeline Updates 45
Coronavirus Infection - Dormant Projects 49
Coronavirus Infection - Product Development Milestones 50
Featured News & Press Releases 50
Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables
Number of Products under Development for Coronavirus Infection, H1 2015 8
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Coronavirus Infection - Pipeline by AstraZeneca PLC, H1 2015 17
Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H1 2015 18
Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2015 19
Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 20
Coronavirus Infection - Pipeline by NanoViricides, Inc., H1 2015 21
Coronavirus Infection - Pipeline by Novavax, Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2015 45
Coronavirus Infection - Dormant Projects, H1 2015 49